Post by bobw on Sept 24, 2013 10:25:56 GMT -5
An interesting post from YMB:
finance.yahoo.com/mb/MNKD/#mbt=Mannkind%2520is%2520in%25u2026&mbl=http%253A%2F%2Ffinance.yahoo.com%2Fmbview%2Fthreadview%2F%253F%2526bn%253D0243242e-59fb-3abc-8d27-962c7bf26a1d%2526tid%253D1379511169132-5dba89bc-cf14-43a4-ae07-43612d412c52%2526tls%253Dla%25252Cd%25252C7%25252C3&mbtc=mb-tab-topic
hytekvideo • Sep 18, 2013 9:32 AM Flag21
users liked this posts users disliked this posts 1 Reply
Mannkind is in the Lead, according to Novo CEO that guarantees 5-10 percent of Market.Novo's CFO has recently made some telling statements: He has stated that not sticking yourself with needles is not really important to diabetics, but his company is working on basal insulins that don't have to be taken by needle every day. That is their argument about Mannkind, that convenience is not the important.
See how that works in a room full of diabetic Millenials. The CFO also stated that typically new insulins, as they are few and far between, garner 5-10 percent of market share in a specific market and segment when introduced. Clearly, he is talking about a product hitting the ground with a large sales force like his or Lilly's or Sanofi's, BUT he is saying that under his company he would expect Mannkind to hit a billion dollar run rate within 18 months of launch. That would easily justify a mid teens stock price for Mannkind. Novo is the leader in Prandial insulin, so they have the most to loose from Mannkind's launch and are the least likely to partner as they are a smaller company, with less capital resources, and don't want to cannibalize existing products.
Nevertheless,
Novo Nordisk’s FIAsp is the ultra-rapid-acting insulin second closest to market, behind Mannkind's Afrezza
and it has been stated:
if the insulins can drop blood glucose more quickly, patients would be less likely to stack insulin and experience delayed hypoglycemia. Last, a faster-acting insulin would significantly improve efforts to develop an artificial pancreas, since closed-loop algorithms’ ability to control glucose tightly is limited by the slow speed of available rapid-acting analogs.
THE ARTIFICIAL PANCREAS PROJECT is already using and testing Afrezza from Mannkind. A successful artificial pancreas will use fast acting insulin, such as Afrezza, not long acting Basal, because they will be able to micro dose on a continual, as needed basis.
This means Afrezza could potentially become the best sellling insulin in the world and this is what AL meant... Less
finance.yahoo.com/mb/MNKD/#mbt=Mannkind%2520is%2520in%25u2026&mbl=http%253A%2F%2Ffinance.yahoo.com%2Fmbview%2Fthreadview%2F%253F%2526bn%253D0243242e-59fb-3abc-8d27-962c7bf26a1d%2526tid%253D1379511169132-5dba89bc-cf14-43a4-ae07-43612d412c52%2526tls%253Dla%25252Cd%25252C7%25252C3&mbtc=mb-tab-topic
hytekvideo • Sep 18, 2013 9:32 AM Flag21
users liked this posts users disliked this posts 1 Reply
Mannkind is in the Lead, according to Novo CEO that guarantees 5-10 percent of Market.Novo's CFO has recently made some telling statements: He has stated that not sticking yourself with needles is not really important to diabetics, but his company is working on basal insulins that don't have to be taken by needle every day. That is their argument about Mannkind, that convenience is not the important.
See how that works in a room full of diabetic Millenials. The CFO also stated that typically new insulins, as they are few and far between, garner 5-10 percent of market share in a specific market and segment when introduced. Clearly, he is talking about a product hitting the ground with a large sales force like his or Lilly's or Sanofi's, BUT he is saying that under his company he would expect Mannkind to hit a billion dollar run rate within 18 months of launch. That would easily justify a mid teens stock price for Mannkind. Novo is the leader in Prandial insulin, so they have the most to loose from Mannkind's launch and are the least likely to partner as they are a smaller company, with less capital resources, and don't want to cannibalize existing products.
Nevertheless,
Novo Nordisk’s FIAsp is the ultra-rapid-acting insulin second closest to market, behind Mannkind's Afrezza
and it has been stated:
if the insulins can drop blood glucose more quickly, patients would be less likely to stack insulin and experience delayed hypoglycemia. Last, a faster-acting insulin would significantly improve efforts to develop an artificial pancreas, since closed-loop algorithms’ ability to control glucose tightly is limited by the slow speed of available rapid-acting analogs.
THE ARTIFICIAL PANCREAS PROJECT is already using and testing Afrezza from Mannkind. A successful artificial pancreas will use fast acting insulin, such as Afrezza, not long acting Basal, because they will be able to micro dose on a continual, as needed basis.
This means Afrezza could potentially become the best sellling insulin in the world and this is what AL meant... Less